Opendata, web and dolomites

QSEIF SIGNED

QSEIF: The new pathogen, DNA and immunological testing platform

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 QSEIF project word cloud

Explore the words cloud of the QSEIF project. It provides you a very rough idea of what is the project "QSEIF" about.

provides    animal    717    pcr    designed    performance    tests    iso    internal    farm    sme    pathogen    biosafety    maturity    immunological    2021    ifs    environment    32m    man    detection    first    brc    vaccination    thanks    smes    instrument    qseif    care    safety    disruptive    suit    human    reducing    customer    laboratory    space    install    22000    technological    envision    company    certifications    international    food    2024    feasibility    microbiology    cover    perform    strategies    immunoassays    period    limit    profit    operability    specially    88    laboratories    automation    lauch    immumological    imicroq    diagnosis    40    lower    validate    point    regulatory    involvement    magnitude    time    orders    investment    hour    companies    diagnostic    24    sectors    accumulated    months    net    reference    fulfil    revenue    platform    elisa    commercial    financial    viability    disease    innovation    affordability    infectious    processors    sales    2m    dynamic    total    market    breakthrough   

Project "QSEIF" data sheet

The following table provides information about the project.

Coordinator
IMICROQ SL 

Organization address
address: CALLE FERRO 6 NAVE 7 POLIGON INDUSTRIAL RIU CLAR
city: TARRAGONA
postcode: 43006
website: www.imicroq.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 1˙690˙250 €
 EC max contribution 1˙183˙175 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-03-01   to  2021-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    IMICROQ SL ES (TARRAGONA) coordinator 1˙183˙175.00

Map

 Project objective

iMiCROQ aims to bring to the market the first integrated platform for pathogen, immumological and PCR testing specially designed to cover the whole needs at farm level, internal control laboratories, food processors and point-of-care infectious disease testing. Thanks to its affordability, QSEIF will allow from SMEs to large companies to improve their biosafety and internal microbiology control to fulfil their requirements from ISO 22000, BRC or IFS certifications, while reducing the needs in laboratory space, the investment, the test cost and man-hour involvement thanks to higher automation. Another important breakthrough in the immunological sector is that QSEIF provides 1-2 orders of magnitude lower limit of detection, less time and better dynamic range than current reference test ELISA. We envision three important applications of this disruptive platform in the areas of: (1) Food Safety; (2) Vaccination Control; (3) Immunoassays for human and animal diagnosis. We will reach end-users from all these sectors according to different commercial strategies that have been tailored to suit each type of customer. The main objective of this project is to increase the technical maturity of the platform and to validate its performance and operability in operational environment with different end-users. After this 24 months project, we will lauch QSEIF to the market with the aim of becoming an international reference in the diagnostic market. The viability of the technological, regulatory, market and financial aspects of the QSEIF innovation project were assessed through a feasibility analysis carried out in SME Instrument Phase I. From the analysis, we expect to install 717 devices that would perform 5.2M tests in a five year period. By then, QSEIF platform will bring an accumulated Net Profit of 5,32M€ by 2024. It is expected that sales of QSEIF will represent 40% of the company’s total revenue in 2021, growing to 88% by 2024.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "QSEIF" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "QSEIF" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

In-Heal (2019)

Standardised administration device for raw medical herbs

Read More  

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More  

ChromicGlass (2019)

FAST-RESPONSIVE and LONG-LASTING TRANSPARENT PHOTOCHROMIC FILMS

Read More